Document is current
Any future updates will be listed below
-
Authors
Magner, Martin http://orcid.org/0000-0002-5883-9509
Almássy, Zsuzsanna
Gucev, Zoran
Kieć-Wilk, Beata
Plaiasu, Vasilica
Tylki-Szymańska, Anna
Zafeiriou, Dimitrios
Zaganas, Ioannis
Lampe, Christina
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical
- License Information
-
More Information
Article History
Received: 21 January 2022
Accepted: 26 April 2022
First Online: 10 May 2022
Declarations
:
: Not applicable.
: Not applicable.
: MM received speaker honoraria from BioMarin, Takeda and Chiesi, and consultancy fees from BioMarin. ZA received consultancy fees from BioMarin. ZG received speaker and advisory board honoraria from Novo Nordisk, Merck, and Takeda and consultancy fees from BioMarin, BKW received consultancy fees from BioMarin. VP received consultancy fees from BioMarin. ATS received speaker honoraria and/or travel grants from BioMarin, Sanofi Genzyme, Alexion, Chiesi, and Shire/Takeda and consultancy fees from BioMarin, DZ received honoraria, travel and research grants from Sanofi-Genzyme, Takeda, BioMarin, Novartis, Biogen, UCB and consultancy fees from BioMarin. IZ received consultancy honoraria from Akcea, Alnylam, BioMarin, Genesis Pharma, Roche, Specifar/Teva. CL received advisory board and speaker honoraria, travel expenses and consultancy honoraria from Sanofi, BioMarin, Amicus, Alexion, Takeda Chiesi, Regenxbio.
